by Hanna | May 21, 2024 | Blog Post, PULSE Partner
How mergers and acquisitions drive innovative cures and New Jersey’s economy New Jersey has long been home to some of the world’s leading research-based biopharmaceutical companies. Many have made New Jersey a base for their global, North American, or U.S. operations....
by Hanna | May 15, 2024 | Blog Post, Innovations Advanced by M&A
This blog is another installment in a series, Innovations Advanced by M&A, that underscores the importance of mergers and acquisitions in ensuring a competitive and vibrant biopharmaceutical landscape for patients. You can find previous blogs in this series here....
by Hanna | May 8, 2024 | Blog Post
The United States is home to more than 2,300 life sciences companies – including more than 85 percent of the world’s small, early-stage biopharmaceutical companies – each competing to bring new treatments and cures to patients. Within this dynamic and competitive...
by Hanna | May 1, 2024 | Blog Post, Innovations Advanced by M&A
This blog is another installment in our series, Innovations Advanced by M&A, which underscores the importance of mergers and acquisitions in ensuring a competitive and vibrant biopharmaceutical landscape for patients. You can find previous blogs in this series...
by Hanna | Apr 25, 2024 | Blog Post
Bipartisan policymakers continue to raise concerns about the recently finalized 2023 Merger Guidelines and their impact on early-stage companies. Last week, the House Committee on Small Business wrote to the Federal Trade Commission (FTC) and Antitrust Division of the...
by Hanna | Apr 24, 2024 | Blog Post
Speaking to antitrust experts at the ABA’s 2024 Spring Antitrust Meeting, Andrew Forman, deputy assistant attorney general at the Department of Justice’s (DOJ) Antitrust division, suggested that the Federal Trade Commission (FTC) and DOJ’s forthcoming changes to the...
